Published in Gene Therapy Weekly, October 23rd, 2008
"The AR has been considered as a critical determinant for the development and progression of human prostate cancers. In this study, we sought to identify the PI3K isoforms involved in AR transactivation. Using a gene-specific small interference RNA (siRNA) approach, we determined that the regulatory isoform p85 alpha and the catalytic isoform p110 beta, but not p110 alpha, were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2008-10-23)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.